Abstract: A method of increasing an activity of a podophyllotoxin or a derivative thereof is disclosed. The method comprises contacting the podophyllotoxin or the derivative with a liquid composition having a liquid and nanostructures, each of the nanostructures comprising a core material of the nanometric size surrounded by an envelope of ordered fluid molecules, the core material and the envelope of ordered fluid molecules being in a steady physical state, thereby increasing the activity of the podophyllotoxin or the derivative. Pharmaceutical compositions comprising same and uses thereof are also disclosed.

Abstract: An object of the present invention is to provide a whitening agent containing a novel whitening substance as an effective ingredient. The above object is attained by providing a whitening agent containing equol and/or equol glycoside, in which one or more glycosyl groups bind to the hydroxyl group(s) of equol, as an effective ingredient.

Abstract: Exemplary embodiments of this invention encompass a method for degrading rebaudioside A and the rebaudioside A derivative products derived therefrom. In particular, this invention relates to a method for degrading rebaudioside A compositions to obtain rebaudioside A derivative products suitable for use as sweetener compositions.

Abstract: The invention relates to a pharmaceutical composition comprising a glucuronate, glucoside, and/or sulfo conjugate of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or such a conjugate of a derivative of 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, or a physiologically well tolerated salt of such a conjugate.

Abstract: The invention provides coumarin compounds, in particular glycosidic coumarin compounds, useful in the treatment of dermatophyte fungal infections.

Abstract: Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof The invention relates to substituted heterocyclic fluoroglycoside derivatives of the formula I in which the radicals have the stated meanings, and their physiologically tolerated salts and processes for their preparation. The compounds are suitable for example as antidiabetics.

Abstract: The invention relates to a composition containing total triterpenoid sapogenins extracted from bamboo, the preparation method and use thereof. These total triterpenoid sapogenins are extracted from many parts of bamboo such as bamboo shavings in Gramineae by CO2 Supercritical Fluid Extraction technique. In the extract, the content of total triterpenoid sapogenins is 10-90%, while the contents of friedelin and lupenone are 5-35% and 1-10%, respectively. The extract in the invention has good physiological and pharmacological activities such as anti-free radical, anti-oxidation, anti-tumor and anti-hypertension. It can be used in medicines or functional foods for the treatment or prevention of cardiovascular and cerebrovascular diseases and tumor. It is also useful in cosmetics field.

Abstract: A glucose compound represented by Formula (I): wherein, R11 and R12 each independently represent an alkyl group having 1 to 10 carbon atoms or an alkenyl group having 2 to 10 carbon atoms, wherein one CH2 group or two or more non-adjacent CH2 groups in the alkyl and alkenyl groups may be replaced by O; L1 represents —OCO—*, —OCH2—* (binding to B at the * side), or a single bond; A and B each independently represent a trans-1,4-cyclohexylene group which may be substituted or a 1,4-phenylene group which may be substituted; and R13 and R14 each independently represent a hydrogen atom or an acyl group having 1 to 10 carbon atoms; and a cellulose composition, a cellulose film, an optical film, a polarizing plate, a liquid crystal display device, and a retardation-increasing agent which have the glucose compound.

Abstract: An expression inhibitor of a nuclear transcription factor AP-1 is provided that is excellent in safety and activity of inhibiting the expression of a nuclear transcription factor AP-1. The AP-1 expression inhibitor of the present invention is characterized by containing chamaemeloside. In the present invention, chamaemeloside may be contained as an extract of Roman chamomile or German chamomile. The chamaemeloside is contained in Roman chamomile or German chamomile. Conventionally, Roman chamomile and German chamomile have been used as cosmetic materials and herb teas and have no problems in safety. An extract of Roman chamomile or German chamomile and chamaemeloside inhibit the expression of the AP-1 at the gene level (see FIG. 2) and therefore are excellent in an inhibition effect as compared to a conventional inhibitor that inhibits binding of the AP-1 to DNA.

Abstract: Novel ent-kaurene diterpene compound and its derivatives, their preparation methods and their use. ent-Kaurene diterpene in the present invention could be used as desired intermediates for preparing asymmetric organic compounds and medicaments, and could be used as antitumor agent, anti-inflammatory agent and immune agent etc. The said ent-kaurene diterpene compound could be condensed with hydroxyl compounds to obtain various acetal derivatives, could be reacted with amine compounds to obtain various amino derivatives, and could be reacted with acyl halide or acid anhydride to obtain various acyl derivatives.

Abstract: This invention relates to novel homotopic prodrugs and medicaments and methods for their preparation, testing and use. In one embodiment, the homotopic prodrug has the general formula wherein is a biologically-active moiety comprising a carboxylic acid functional group, and Rb is a homotopically-symmetrical alcohol bonded to the biologically-active moiety through the carboxylic acid functional group to form an ester linkage, as well as optical isomers, enantiomers, pharmaceutically acceptable salts, biohydrolyzable amides, esters, and imides thereof and combinations thereof.

Abstract: Methods for assaying ?-L-iduronidase enzymatic activity and methods for screening newborns for Mucopolysaccharidosis Type-I.

Abstract: This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder.

Abstract: Compositions and methods for treatment of disease with acetylated disaccharides and analogs thereof are provided.

Abstract: The invention provides the use of ursolic acid saponin and oleanolic acid saponin of formula (I) in preparing medicaments for increasing leucocytes and/or platelets. The invention also provides a pharmaceutical composition containing the same compound. The invention utilizes the cheap and accessible ursolic acid and oleanolic acid which are widely present in natural plants as raw materials, introduces monosaccharyls or oligosaccharyls by structural modification. It is proved by pharmacological tests that the compound of formula (I) have an activity of obviously increasing leucocytes and/or platelets.

Abstract: The present invention relates to the use of oleanane-type triterpene saponin compounds, which are effective for improving memory and learning ability, as an effective ingredient of drugs for the treatment and prevention of dementia and mild cognitive impairment and health foods for the improvement of brain functions including cognitive function.

Abstract: The invention provides novel saponin mixtures and compounds which are isolated from the species Acacia victoriae and methods for their use. These compounds may contain a triterpene moiety, such as acacic or oleanolic acid, to which oligosaccharides and monoterpenoid moieties are attached. The mixtures and compounds have properties related to the regulation of apoptosis and cytotoxicity of cells and exhibit potent anti-tumor effects against a variety of tumor cells.

Abstract: Sweeteners on the basis of a simultaneously transglucosylated sweet glycoside mixture of Stevia rebaudiana Bertoni are prepared. The transglucosylation was developed in the presence of starch under the action of cyclodextrin glucanotransferase. The remaining maltodextrins are transformed to the fructose-terminated oligosaccharides by the addition of sucrose. The sweeteners are purified to not less than 98% content of sweet glycosides and derivatives. The preparations are almost non-caloric, non-cariogenic, non-bitter, non-lingering sweeteners, which may be advantageously applied in foods, beverages, cosmetics and milk products.

Abstract: A dicarboxylic acid compound obtainable by oxidative degradation of pradimicin antibiotics, which are antibiotics consisting of the benzonaphthacene skeleton, a D-amino acid side chain and a sugar chain, for the second saccharide residue of the sugar chain, and use thereof utilizing a specific microorganism binding property thereof are provided. The dicarboxylic acid compound has significantly improved water-solubility compared with the raw material antibiotics, whist maintaining the specific microorganism binding property.

Abstract: Exemplary embodiments of this invention encompass a method for purifying a low purity steviol glycoside composition. In particular, this invention relates to a method for purifying low purity steviol glycoside compositions to obtain substantially pure steviol glycoside compositions comprising approximately 95% or greater steviol glycosides and approximately 75% or greater rebaudioside A with a single crystallization step.

Abstract: This disclosure provides improved derivatives of artemisinin; pharamaceutical compositions containing these compounds; methods for preparing these compounds and compositions; methods of using these compounds and compositions for preventing, controlling or treating infectious diseases including but not limited to parasitic infectious diseases such as T. gondii infection, trypanosome parasite infection, plasmodia parasite infection, and cryptosporidium parasite infection; methods for preventing, controlling or treating toxoplasma infection; and methods for treating psychiatric disorders associated with toxoplasma infection including but not limited to schizophrenia using the disclosed compounds and compositions alone or in combination with one or more antipsychotic drugs.

Abstract: New and useful compounds C. roseus cultured hairy roots are provided, by Isolating flavone glycosides together with a pharmaceutically acceptable carrier This is accomplished by immersing powdered the hairy roots in methanol to produce an extract, concentrating the extract, resuspending the extract in water, extracting the compound with organic solvent, and isolating the compound from the organic solvent.

Abstract: Novel thiophene glycoside derivatives of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for their preparation are disclosed. The compounds are suitable, for example, as antidiabetics.

Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.

Abstract: An organized mobile multicomponent conjugate (OMMC) and method of using to enhance binding of weakly binding compounds to a target. A lamellar structure containing at least two binding compounds is assembled under conditions in which the binding compounds self-regulate in or on the lamellar structure, forming a cooperative ensemble that is capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface, and may be connected by a linker. The OMMC may contain an effector molecule, such as a diagnostic or therapeutic agent, for administration to a patent who is then diagnosed or treated using the effector molecule.

Abstract: The present invention relates to conjugates of therapeutically useful anthracyclines with carriers such as polyclonal and monoclonal antibodies, proteins or peptides of natural or synthetic origin; methods for their preparation, pharmaceutical composition containing them and use thereof in treating certain mammalian tumors.

Abstract: The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X1 represents N or CR1; X2 represents N or CR2; X3 represents N or CR3; X4 represents N or CR4; and with the proviso that one or two of X1 to X4 represent N; R represents optionally substituted C3-8 cycloalkyl, optionally substituted C6-10 aryl, etc.; R1 to R4 represent H, a halogen atom, etc.) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an excellent inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complications, obesity or the like, pharmaceutical compositions comprising the same, and medicinal uses thereof.

Abstract: The present invention provides compositions and methods useful for preparing and using analogs, derivatives, and modifications of kaempferols that have anti-neoplastic activity. More specifically, the compounds are analogs, derivatives, and modifications of SLO1O1. The invention further provides compounds that are inhibitors of rsk activity. The invention further provides compounds that selectively inhibit excessive rsk activity in cancers. The present invention further provides methods for treating cancer using compounds of the invention.

Abstract: Flavonoids are obtained from plants that overexpress an ANT1 gene compared to wild-type plants. The plant may be a transgenic plant that contains a transformation vector that causes the overexpression of ANT1. Alternatively, the plant can be selectively bred to have an allele of or mutation in an endogenous ANT1 gene that causes the overexpression of ANT1 compared to plants lacking the allele or mutation.

Abstract: Disclosed herein are novel naphthalene-2-carboxylate derivatives of Formula (I), which are useful for the synthesis of gemcitabine, as well as a preparation method. The novel derivatives have naphthalene-2-carboxlate as the hydroxy protecting group of 2-deoxy-2,2-difluoro-pentofuranose-1-ulose. (I) wherein R1 and R2 are each independently hydrogen, methyl, chloro, fluoro, bromo, iodo, methoxy, ethoxy or nitro.

Abstract: The present invention relates compounds of the formula (I) oligosaccharide-spacer-A (1), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising two to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-III mediated) anti-Xa activity per se; the spacer is an essentially pharmacologically inactive flexible linking residue having a chain length of 10 to 70 atoms; A is the residue —CH[NH—SO2—R1][CO—NR2—CH(4-benzamidine)-CO—NR3R4], wherein R1 is phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, (iso)quinolinyl, tetrahydro(iso)quinolinyl, 3,4-dihydro-1H-isoquinolinyl, chromanyl or the camphor group, which groups may optionally be substituted with one or more substituents selected from (1-8C)alkyl or (1-8C)alkoxy; and wherein R2 and R3 are independently H or (1-8C)alkyl; R4 is (?8C)alkyl or (3-8C)cycloalkyl; or R3 and R4 together with the nitrogen atom to

Abstract: The present invention relates to a high throughput screening method of a binding inhibitor between caspase3 and xIAP and chromomycin screened using the same, and more specifically, the present invention provides a method for screening anticancer substance, the method comprising the steps of reacting caspase3 or xIAP and candidate inhibitors of the binding between caspase3 and xIAP on a biochip for detecting caspase3:xIAP interaction, and selecting a candidate substance inhibiting the binding of caspase3 to xIAP as an anticancer substance, and an anticancer agent inhibiting caspase3:xIAP binding, which is screened by the above method. According to present invention, it is possible to develop a target-oriented anticancer agent focused on xIAP and caspase3, apoptosis-related proteins and thus it can be applied to tailored medication and combination therapy.

Abstract: The invention relates to a gem-difluoride glycoconjugated compound with formula (I): where R represents II or a benzyl, acetyl, benzoyl alkyl group, R1 and R2 may be identical or different and represent H or an alkyl, benzyl, benzoyl, acetyl, pivaloyl, trialkylsilyl, tertiobutyldiphenylsilyl protective group or an acetal group of the CR?R? type, where R? and R? may be identical or different and represent H or an alkyl, aryl, benzyl or thiophene group, R3 represents H or an alkyl, benzyl, benzoyl, acetyl, pivaloyl, trialkylsilyl or tertiobutyldiphenylsilyl protective group, R4 represents OR?, NGR?GR?, N3, or a phthalimide, where R? represents H or an alkyl, benzyl, benzoyl, acetyl, pivaloyl, trialkylsilyl or tertiobutyldiphenylsilyl protective group, GR? and GR? may be identical or different and represent II or an alkyl, benzyl, benzoyl, acetyl, alkyloxycarbonyl, allyloxycarbonyl or benzyloxycarbonyl group, R5 represents a free or protected hydroxyl group or a halogen, R6 represents H or an alkyl, acetyl, benz

Abstract: Various compounds obtained from plants of the Barringtonia species which are derived from Barringtoside A and Barringtoside C as precursor compounds which especially have an arabinopyranosyl substituent at the 21 position which may optionally be further substituted with benzoyl, dibenzoyl, methyl butanoyl, methyl butyryl or tigloyl at the 3 or 4 positions. Alternatively at the 21 position there is provided tigloyl, benzoyl or dibenzoyl substituents.

Abstract: The invention relates to the preparation of phenolics derivatives by enzymatic condensation of phenolics selected among pyrocatechol or its derivatives with the glucose moiety of sucrose. The production of said phenolics derivatives is achieved with a glucosyltransferase (EC 2.4.1.5). These O-?-glucosides of selected phenolics are new, have a solubility in water higher than that of their parent polyphenol and have useful applications in cosmetic and pharmaceutical compositions, such as antioxidative, antiviral, antibacterial, immune-stimulating, antiallergic, antihypertensive, antiischemic, antiarrhythmic, antithrombotic, hypocholesterolemic, antilipoperoxidant, hepatoprotective, anti-inflammatory, anticarcinogenic antimutagenic, antineoplastic, anti-thrombotic, and vasodilatory formulations, or in any other field of application.

Abstract: Compounds having useful biological activity, particularly antioxidant and anti-inflammatory activity, derived from Centipeda cunninghamii, and biologically active derivatives thereof, pharmaceutical compositions comprising these compounds, and prophylactic and therapeutic use of the compounds.

Abstract: Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.

Abstract: The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl, etc.; one of Q and T represents a group selected from the following: and the other represents -Z-Ar wherein Z represents —O—, —S—, etc.; Ar represents an optionally substituted C6-10 aryl, etc.; R represents an optionally substituted C3-8 cycloalkyl, an optionally substituted C6-10 aryl, etc., pharmaceutically acceptable salts thereof, and prodrugs thereof, which exhibit an excellent inhibitory activity in human sodium/glucose cotransporter (SGLT) and are useful as agents for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose (diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, etc.

Abstract: The present invention provides pyrazole derivatives represented by the general formula: wherein R1 represents H, an optionally substituted C1-6 alkyl group etc.; one of Q and T represents a group selected from the following groups: and the other represents —(CH2)n—Ar wherein Ar represents an optionally substituted C6-10 aryl group or an optionally substituted C1-9 heteroaryl group; and n represents an integral number from 0 to 2, an optionally substituted C1-6 alkoxyl group, an optionally substituted amino group, an optionally substituted C2-9 heterocycloalkyl group or an optionally substituted heterocycle-fused phenyl group; R represents an optionally substituted C3-8 cycloalkyl group, an optionally substituted C6-10 aryl group etc.

Abstract: The present invention provides compounds and methods of using them for preparing bicyclic nucleosides. The bicyclic nucleosides are useful for preparing chemically modified oligomeric compounds. Oligomeric compounds comprising these bicyclic nucleosides have enhanced properties such as increased nuclease resistance.

Abstract: Compounds of 5-thioxylopyranose, preferably derivatives of the 5-thioxilopyranose type, a method for preparing such compounds, and the use of such compounds as an active ingredient in pharmaceutical compositions which are useful, in particular, for treating or inhibiting thrombosis or heart failure or thromboembolic disease states.

Abstract: The invention relates to pharmaceutical compositions comprising benzopyranone derivatives for the treatment of Severe Acute Respiratory Syndrome (SARS).

Abstract: Disclosed herein are novel probes, which can be used to detect and identify target molecules of interest in a sample. The disclosed probes can be used to monitor conformational changes induced by molecular recognition events in addition to providing signaling the presence and/or identity of a target molecule. Methods, including solid phase synthesis techniques, for making probe molecules that exhibit changes in their optical properties upon target molecule binding are described in the disclosure. Also disclosed herein are novel chromophore moieties, which have tailored fluorescent emission spectra.

Abstract: The present invention relates to a flavonoid compound having an antiviral activity, more particularly to a flavonoid compound obtained by extracting Houttuynia cordata with methanol and separating/purifying with chromatography, a method for efficient extraction and purification of the same and an antiviral composition comprising the compound as an active ingredient.

Abstract: Provided is a new anti-cancer agent lower in cell toxicity. The present invention provides the compounds represented by the general formula of “Formula 1” or the salt thereof. The compounds are compounds having an organic group introduced on a particular ketone group of VST that functions to inhibit induction of GRP 78 expression, similarly to VST, and is applicable, for example, as an anti-cancer agent. The compounds are also advantageous in that it is less toxic than VST and has lower adverse reaction.

Abstract: Disclosed are compositions related to water soluble selective COX-2 inhibitors and methods of using the inhibitors (including Esculentoside A and derivatives thereof).

Abstract: This invention provides compositions, methods and process of producing extracts from Xanthoceras sorbifolia. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for treating breast, leukocyte, liver, ovarian, bladder, prostate, bone or brain cancer. This invention provides compounds comprising at least one sugar, a triterpene, such as Sapogenin, and at least one side chains at Carbon 21 and 22, such as Angeloyl groups. The compounds of the present have various pharmaceutical and therapeutic applications, including treating breast, leukocyte, liver, ovarian, bladder, prostate, bone or brain cancer.

Abstract: The present invention relates to compositions and methods for preparing pharmaceutical compositions. In some embodiments, the invention includes compounds and methods of resolving chiral compounds. In some embodiments, the invention includes chiral and crystalline compositions and hydrates. In some embodiments, the invention contemplates compositions comprising camptothecin derivatives and synthetic intermediates thereof. In some embodiments, the invention includes methods of protecting, inserting, modifying, separating isomers, and removing chemical groups.

Abstract: Novel compounds such as compounds designated herein as Y or Y3, Y1, Y2, Y8, Y9 and Y10 are disclosed. These compounds have anticancer activity. The compounds of the present invention are obtainable from plants in the sapindaceae family, such as Xanthoceras sorbifolia, or other natural sources or products. The compounds of the present invention may also be synthesized chemically.

Abstract: The present application describes deuterium-enriched odiparcil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.